RE:RE:RE:PR more partial responses form Adlay trial...
By the data cutoff date of June 2nd, 2022, a total of 10 female patients were enrolled, with a median age of 58 years (range 36-67). Two (20%) patients had failed more than one prior line of endocrine therapy for advanced/metastatic disease, and 3 (30%) patients were previously treated with a CDK4/6 inhibitor.
8 /10 patients who had PR or SD continue to receive treatment as of the data cut.
In other words these 8 patients remain ALIVE and WELL.